Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
NasoVAX, an adenovirus-based intranasal flu vaccine, shows tolerability, safety, and higher cellular immune response compared to an injectable vaccine.
Treatment with intravenous and oral delafloxacin, a fluoroquinolone antibiotic with gram-negative and gram-positive activity, was comparable to vancomycin/aztreonam in improving clinical signs and symptoms in acute bacterial and skin structure infections.
Once-daily single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults who have virologic suppression of HIV-1 infection has a high efficacy and safety profile.
Prophylactic antibiotic prescriptions before dental procedures may not be limited to indicated cardiac diagnoses, as per present guidelines, according to a study presented at IDWeek 2018 in San Francisco.
No significant differences in clinical cure rates were observed between short-course and prolonged-course antimicrobial therapy in patients with intraabdominal infections.
Rates of urinary tract infection recurrence after antibiotic depletion did not differ significantly between treatment durations of 7 days, 10 days, and 14 days.
Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.
In patients taking multiple antibiotics, proton pump inhibitors, or histamine receptor antagonists, the concurrent use of probiotics was associated with an increased incidence of Clostridium difficile infection
For patients with CAP, antibiotic regimens including a fluoroquinolone may reduce mortality risk by 1-2% compared to beta-lactams and cephalosporins alone.
The combination of daptomycin with fosfomycin demonstrates increased efficacy in treating methicillin-resistant Staphylococcus aureus bacteremia compared with daptomycin alone.
A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.
The use of fluoroquinolones in stable patients with community-acquired pneumonia can be reduced with stewardship programs that share antibiotic use data and provide guidance for step-down therapy.